Please login to the form below

Not currently logged in
Email:
Password:

non-small cell lung cancer

This page shows the latest non-small cell lung cancer news and features for those working in and with pharma, biotech and healthcare.

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma

BMS has had mixed success in gaining NICE approval for Opdivo across its many cancer indications. ... A year ago Opdivo gained NICE approval for second line use in the biggest single cancer patient group, non-small cell lung cancer (NSCLC), but its main

Latest news

  • MSD wins key EU approval for Keytruda, Alimta combo MSD wins key EU approval for Keytruda, Alimta combo

    Immunotherapy blockbuster Keytruda has received another boost with the European approval of its use in combination with Lilly’s Alimta plus chemotherapy in non-small cell lung cancer (NSCLC). ... can renew our efforts to reach the best possible

  • FDA gives Loxo breakthrough tag for second cancer drug FDA gives Loxo breakthrough tag for second cancer drug

    The BTD covers patients with metastatic RET-fusion-positive non-small cell lung cancer (NSCLC) who have progressed despite earlier therapy with chemotherapy and checkpoint inhibitors, as well as last-line ... including patients with brain metastases, and

  • Home-grown colorectal cancer drug approved in China Home-grown colorectal cancer drug approved in China

    Pfizer abandoned a trial of its lung cancer drug Sutent (sunitinib) in first-line CRC a few years ago, while AstraZeneca’s cedirinib failed in this form of cancer as well ... The Chinese company is now planning to extend fruquintinib’s use into

  • Novartis wins key adjuvant Taf/Mek approval in Europe Novartis wins key adjuvant Taf/Mek approval in Europe

    including a go-ahead last year in BRAF V600-postitive non-small cell lung cancer (NSCLC). ... talk of using the cancer immunotherapies and small-molecule BRAF/MEK pair in combination.

  • AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan AZ’s soon-to-be lung cancer blockbuster Tagrisso approved in Japan

    mutation-positive non-small cell lung cancer (NSCLC). ... According to the company, up to 40% of lung cancer patients in Asia have EGFRm NSCLC, and these patients are particularly sensitive to treatment with EGFR-TKIs, which block the

More from news
Approximately 1 fully matching, plus 536 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    had transformative results in some diseases such as melanoma, non-small cell lung cancer and bladder cancer – among others. ... Non-small cell lung cancer (NSCLC) is a prime example of the impact the new PD-(L) 1 drugs can have.

  • The good, the bad and the ugly The good, the bad and the ugly

    Merck’s success in oncology will likely continue, driven by Keytruda’s lead in the frontline non-small cell lung cancer setting, ”says Cai Xuan, senior analyst, oncology and haematology, GlobalData. ... It will also be interesting to see how gene

  • Deal Watch February 2017 Deal Watch February 2017

    triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. ... TROP-2 is a cell surface receptor which is over-expressed by many human tumours, including cancers of the breast, colon and

  • Pharma deals during October 2014 Pharma deals during October 2014

    Now with a headline of $847m, Aduro receives an upfront of $30m with $817m in milestones for ADU 214 in the treatment of lung cancer. ... This month's big pharma collaborations are in oncology, firstly where Novartis and BMS have entered a clinical

  • Pharma deals during August 2014 Pharma deals during August 2014

    Oncothyreon's clinical stage pipeline includes the immunotherapy candidates tecemotide (phase III - Stage III non-small cell lung cancer) and ONT-10 (phase 1 - solid tumour treatment), and the only ... 2 small molecule inhibitor in clinical development,

More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.

Latest appointments

  • Merck appoints ex-Pfizer exec as global head of oncology Merck appoints ex-Pfizer exec as global head of oncology

    In this role, she will be responsible for defining the pharmaceutical company's integrated global oncology strategies and delivering therapeutic launches, including the commercial launch of Avelumab, a non-small cell ... lung cancer therapy, which is

  • BIND Therapeutics appoints Andrew Hirsch as permanent CEO BIND Therapeutics appoints Andrew Hirsch as permanent CEO

    Its lead compound, BIND-014, is currently in phase II clinical trials for KRAS-mutant and squamous histology non-small cell lung cancer.

  • Axelar appoints Carl Harald Janson as CEO

    I look forward to take this potential novel cancer treatment to proof-of-concept,” said Janson. ... The biotech is currently running a randomised phase II clinical trial with AXL1717 in non-small cell lung cancer (NSCLC) patients, while a first-in-man

More from appointments
Approximately 0 fully matching, plus 3 partially matching documents found.

Latest from PMHub

  • Therapy Watch expands oncology and IBD portfolios

    Therapy Watch CML is part of a wider oncology portfolio which already covers Chronic Lymphocytic Leukaemia (CLL), Non-Hodgkin's Lymphoma (NHL), Melanoma, Non-Small Cell Lung Cancer (NSCLC), Prostate Cancer ... PCa), Renal Cell Carcinoma (RCC) and

  • How pembrolizumab will change the management of advanced lung cancer

    How pembrolizumab will change the management of advanced lung cancer. The results of the Phase III KEYNOTE-024 trial of pembrolizumab for non-small cell lung cancer (NSCLC) were presented by ... He explains that “ this data will completely change our

  • A stumble, but not a fall – what’s next for Opdivo?

    In this manner, it can crucially target several cancers, a property that was successfully exploited by BMS and resulted in securing FDA nods for treating non-small cell lung cancer (NSCLC) ... and renal cell carcinoma (kidney cancer).

  • Therapy Watch expands its oncology portfolio

    Therapy Watch expands its oncology portfolio. This month  Therapy Watch Oncology will be expanding its portfolio with the addition of Squamous Cell Carcinoma of the Head and Neck (SCCHN). ... Therapy Watch SCCHN is part of a wider portfolio which covers

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GK Strategy

GK is award-winning independent communications agency specialising in delivering impactful strategies for clients across the healthcare market....

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics